Anidulafungin is the newest addition to the antifungal arsenal. It possesses fungicidal activity against Candida spp., including isolates that are azole and polyene resistant. In addition, it is fungistatic against Aspergillus spp. Anidulafungin is unique in that it possesses no clinically relevant drug interactions and does not require dosage adjustment in renal or hepatic impairment. Anidulafungin was well tolerated in clinical trials and its clinical efficacy has been demonstrated in the treatment of candidemia and other forms of candidiasis.